- Home
- KELYA vs ABVX Comparison
KELYA vs ABVX Comparison
Compare KELYA & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KELYA
- ABVX
- Stock Information
- Founded
- KELYA 1946
- ABVX 2013
- Country
- KELYA United States
- ABVX France
- Employees
- KELYA N/A
- ABVX N/A
- Industry
- KELYA Professional Services
- ABVX
- Sector
- KELYA Consumer Discretionary
- ABVX
- Exchange
- KELYA Nasdaq
- ABVX Nasdaq
- Market Cap
- KELYA 752.3M
- ABVX 722.3M
- IPO Year
- KELYA N/A
- ABVX N/A
- Fundamental
- Price
- KELYA $14.48
- ABVX $6.37
- Analyst Decision
- KELYA Buy
- ABVX Strong Buy
- Analyst Count
- KELYA 1
- ABVX 7
- Target Price
- KELYA $25.00
- ABVX $37.86
- AVG Volume (30 Days)
- KELYA 1.1M
- ABVX 214.7K
- Earning Date
- KELYA 02-13-2025
- ABVX 09-09-2024
- Dividend Yield
- KELYA 2.09%
- ABVX N/A
- EPS Growth
- KELYA 80.11
- ABVX N/A
- EPS
- KELYA 1.16
- ABVX N/A
- Revenue
- KELYA $4,372,900,000.00
- ABVX $9,676,417.00
- Revenue This Year
- KELYA N/A
- ABVX $31.67
- Revenue Next Year
- KELYA $8.21
- ABVX $759.77
- P/E Ratio
- KELYA $12.38
- ABVX N/A
- Revenue Growth
- KELYA N/A
- ABVX 100.87
- 52 Week Low
- KELYA $12.68
- ABVX $5.54
- 52 Week High
- KELYA $25.27
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- KELYA 55.64
- ABVX 35.26
- Support Level
- KELYA $13.87
- ABVX $6.01
- Resistance Level
- KELYA $14.35
- ABVX $6.46
- Average True Range (ATR)
- KELYA 0.45
- ABVX 0.46
- MACD
- KELYA 0.16
- ABVX -0.01
- Stochastic Oscillator
- KELYA 80.87
- ABVX 41.71
About KELYA Kelly Services Inc.
Kelly Services Inc is a provider of workforce solutions and consulting and staffing services. The company's operations are divided into five business segments namely Professional & Industrial, Science, Engineering & Technology, Education, Outsourcing & Consulting, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.